<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0802233219
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Eletrivaz
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ELETRIPTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        73.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APL Health Care Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APL Health Care Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 3103]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Aurobindo Pharma Saudi Arabia Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N02CC06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Eletrivaz contains the active substance eletriptan. Eletrivaz is one of a<br />group of medicines called serotonin receptor agonists. Serotonin is a<br />natural substance found in the brain that helps to narrow the blood vessels.<br />Eletrivaz can be used to treat migraine headache with or without aura in<br />adults. Before the start of a migraine headache, you may experience a<br />phase called an aura, which can involve vision disorders, numbness and<br />speech disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Do not take Eletrivaz,<br />&bull; If you are allergic (hypersensitive) to eletriptan, or any of the other<br />ingredients of this medicine (listed in section 6).<br />&bull; If you have severe liver or kidney disease.<br />&bull; If you have moderate to severe high blood pressure or untreated mild<br />high blood pressure.<br />&bull; If you have ever had heart problems, [e.g. heart attack, angina, heart<br />failure or significant abnormal heart rhythm (arrhythmia), temporary,<br />sudden narrowing of one of the coronary arteries].<br />&bull; If you have poor circulation (peripheral vascular disease).<br />&bull; If you have ever had a stroke (even a mild one that lasted for only a few<br />minutes or hours).<br />&bull; If you have taken ergotamine or medicines like ergotamine (including<br />methysergide) within 24 hours before or after taking Eletrivaz. If you are<br />taking any other medicines that end in &lsquo;triptan&rsquo; (for example sumatriptan,<br />rizatriptan, naratriptan, zolmitriptan, almotriptan and frovatriptan).<br />Please consult your doctor and do not take Eletrivaz, if these statements<br />apply to you now or have applied to you at any time in the past.<br />Warnings and precautions<br />&bull; you have diabetes.<br />&bull; you smoke or use nicotine replacement therapy.<br />&bull; you are male and over 40 years.<br />&bull; you are female and post-menopausal.<br />&bull; you or anybody in your family have coronary artery disease.<br />&bull; you have ever been told that you may have an increased risk of heart<br />disease, discuss this with your doctor before using Eletrivaz.</p><p dir="ltr">Repeat use of migraine medicines<br />If you repeatedly use Eletrivaz or any medicines for the treatment of<br />migraine over several days or weeks, this can cause daily long-term<br />headaches. Tell your doctor if you experience this as you might need to<br />stop treatment for a while.<br />Other medicines and Eletrivaz<br />Tell your doctor or pharmacist if you are taking, have recently taken or<br />might take any other medicines.<br />Taking Eletrivaz together with some medicines may cause serious<br />side effects. Do not use Eletrivaz if:<br />&bull; you have taken ergotamine or medicines like ergotamine (including<br />methysergide) within 24 hours before or after taking Eletrivaz.<br />&bull; you are taking any other medicines that end in &lsquo;triptan&rsquo; (for example<br />sumatriptan, rizatriptan, naratriptan, zolmitriptan, almotriptan and frovatriptan).<br />Some medicines can affect the way Eletrivaz works, or Eletrivaz itself<br />can reduce the effectiveness of other medicines taken at the same<br />time. These include:<br />&bull; Drugs used to treat fungal infections (e.g. ketoconazole and itraconazole).<br />&bull; Drugs used to treat bacterial infections (e.g. erythromycin,<br />clarithromycin and josamycin).<br />&bull; Drugs used to treat AIDS and HIV (e.g. ritonavir, indinavir and nelfinavir).<br />The herbal preparation St John&rsquo;s wort (Hypericum perforatum) should not<br />be taken at the same time as this medicine. If you already take St John&rsquo;s<br />wort, consult your doctor before stopping the St John&rsquo;s wort preparation.<br />Tell your doctor before starting treatment with eletriptan, if you are taking<br />some medicines (commonly referred to as SSRIs* or SNRIs**), for<br />depression and other mental disorders. These medicines may increase the<br />risk of developing serotonin syndrome during combined use with certain<br />migraine medications. See Section 4 Possible Side Effects for more<br />information on the symptoms of serotonin syndrome.<br />*SSRIs- Selective serotonin re-uptake inhibitors<br />**SNRIs Serotonin norepinephrine re-uptake inhibitors<br />Eletrivaz with food and drink<br />Eletrivaz can be used before or after food and drinks.<br />Pregnancy and breast-feeding<br />Ask your doctor or pharmacist for advice before taking any medicine.<br />If you are pregnant or breast-feeding, think you might be pregnant or are<br />planning to have a baby, ask your doctor for advice before taking this medicine.<br />It is recommended to avoid breast-feeding for 24 hours after taking this<br />medicine.<br />Driving and using machines<br />Eletrivaz or the migraine itself may make you sleepy. This medicine may<br />also make you feel dizzy. Therefore avoid driving and using machines<br />during the migraine attack or after taking your medicine.<br />Eletrivaz contains Lactose, the dye Sunset Yellow Aluminium Lake<br />(E110), and Sodium<br />Lactose is a type of sugar. If you have been told by your doctor that you have<br />an intolerance to some sugars, contact your doctor before taking this medicine.<br />The dye FD&amp;C Yellow No.6 Aluminum lake (E110) may cause allergic<br />reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor has told you. Check with<br />your doctor or pharmacist if you are not sure.<br />Adults<br />Your medicine can be taken at any time after the start of the migraine<br />headache, but it is best to take it as soon as possible. However you should<br />only take Eletrivaz during the headache phase of the migraine. You<br />should not take this medicine to prevent a migraine attack.<br />&bull; The usual starting dose is one 40 mg tablet.<br />&bull; Swallow each tablet whole with a drink of water.<br />&bull; If the first tablet does not relieve your migraine, do not take a second<br />tablet for the same attack.<br />&bull; If after a first tablet your migraine is relieved and then comes back, you<br />may take a second tablet. However, after taking the first tablet you must<br />wait at least 2 hours before taking the second tablet.<br />&bull; You should not take more than 80 mg (2 x 40 mg tablets) within 24 hours.<br />&bull; If you find that a dose of one 40 mg tablet does not relieve your<br />migraines, tell your doctor &ndash; he or she may decide to increase the dose<br />to two 40 mg tablets for future attacks.<br />Use in children and adolescents under 18 years<br />Eletrivaz tablets are not recommended for children and adolescents under<br />18 years of age.<br />Elderly<br />Eletrivaz tablets are not recommended for patients over 65 years of age.<br />Kidney Impairment<br />This medicine can be used in patients with mild or moderate kidney<br />problems. In these patients a starting dose of 20 mg is recommended, and<br />the total daily dose should not be more than 40 mg. Your doctor will tell you<br />what dose to take.</p><p dir="ltr">Liver Impairment<br />This medicine can be used in patients with mild or moderate liver problems.<br />No dose adjustment is required for mild or moderate liver impairment.<br />If you take more Eletrivaz than you should<br />If you accidentally take too much Eletrivaz, contact your doctor at once or go<br />to the nearest hospital casualty department. Always take the labelled<br />medicine package with you, whether there is any medicine left or not. Side<br />effects from taking too much Eletrivaz include high blood pressure and heart<br />problems.<br />If you forget to take Eletrivaz<br />If you forget to take a dose, take it as soon as you remember unless it is time<br />for your next dose. Do not take a double dose to make up for a forgotten dose.<br />If you have any further questions on the use of this medicine, ask your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not<br />everybody gets them.<br />Tell your doctor immediately if you experience any of the following<br />symptoms after taking this medicine.<br />&bull; Sudden wheeziness, difficulty in breathing, swelling of eyelids, face or<br />lips, rash or itching (especially affecting the whole body) as this may be<br />a sign of a hypersensitivity reaction.<br />&bull; Chest pain and tightness, which may be intense and involve the throat.<br />These may be symptoms of problems of the blood circulation of the<br />heart (Ischaemic heart disease).<br />&bull; Signs and symptoms of serotonin syndrome which may include<br />restlessness, hallucinations, loss of co-ordination, fast heart beat, increase<br />body temperature, fast changes in blood pressure and overactive reflexes.<br />&bull; Stiffness (Increased muscle tone), Muscle weakness, Back pain, Muscle pain<br />&bull; Generally feeling weak, Feeling hot, Chills, Runny nose, Sweating,<br />Tingling or abnormal sensation, Flushing, Pain<br />Other side-effects that may occur are:<br />Common<br />(may affect up to 1 in 10 people)<br />&bull; Chest pain or tightness or pressure, Heart palpitations, Increased heart rate<br />&bull; Dizziness, Sensation of spinning or whirling (Vertigo), Headache,<br />Feeling sleepy, Reduced sense of touch or pain<br />&bull; Sore throat, Throat tightness, Dry mouth<br />&bull; Abdominal and stomach pain, Indigestion (upset stomach), Nausea<br />(sensation of unease and discomfort in stomach or abdomen with an<br />urge to vomit)<br />&bull; Stiffness (Increased muscle tone), Muscle weakness, Back pain, Muscle pain<br />&bull; Generally feeling weak, Feeling hot, Chills, Runny nose, Sweating,<br />Tingling or abnormal sensation, Flushing, Pain<br />Uncommon<br />(may affect up to 1 in 100 people)<br />&bull; Difficulty breathing, Yawning<br />&bull; Swelling of the face or hands and feet, Inflammation or infection of the<br />tongue, Skin rash, Itching<br />&bull; Increased sense of touch or pain (Hyperaesthesia), Loss of co-ordination,<br />Slow or reduced movement, Tremor, Slurred speech<br />&bull; Not feeling one self (Depersonalisation), Depression, Thinking strangely,<br />Feeling agitated, Feeling confused, Mood swings (Euphoria), Periods of<br />unresponsiveness (Stupor), General feeling of discomfort, Illness or lack<br />of well being (Malaise), Sleeplessness (Insomnia)<br />&bull; Loss of appetite and weight loss (Anorexia), Taste disturbance, Thirst<br />&bull; Degeneration of the joints (Arthrosis), Bone pain, Joint pain<br />&bull; Increased need to pass water (urinate), Problems with urinating,<br />Passing excessive quantity of urine, Diarrhoea<br />&bull; Abnormal vision, Eye pain, Intolerance to light, Dry or watery eyes<br />&bull; Ear pain, Ringing in the ears (Tinnitus)<br />&bull; Poor circulation (Peripheral vascular disorder)</p><p dir="ltr">Rare<br />(may affect up to 1 in 1,000 people)<br />&bull; Shock, Asthma, Hives (Urticaria), Skin disorder, Swollen tongue<br />&bull; Throat or chest infection, Swollen lymph glands<br />&bull; Slow heart rate<br />&bull; Emotionally fragile (mood swings)<br />&bull; Degeneration of joints (Arthritis), Muscle disorder, Twitching<br />&bull; Constipation, Inflamed gullet, Belching<br />&bull; Breast Pain, Heavy or prolonged menstrual periods<br />&bull; Eye infection (Conjunctivitis)<br />&bull; Changes to voice<br />Other side effects reported include, fainting, high blood pressure, inflammation<br />of the large intestine, vomiting, brain and blood vessel-related accident,<br />inadequate heart blood flow, heart attack, heart muscle/artery-related spasm.<br />Your doctor may also take regular blood samples to test for raised liver<br />enzymes or any blood problems.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes<br />any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date which is stated on the blister<br />or carton. The expiry date refers to the last day of that month.<br />Store below 30&deg;C.<br />Do not throw away any medicine via wastewater or household waste. Ask<br />your pharmacist how to throw away medicines you no longer use. These<br />measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">The active ingredient is eletriptan (as eletriptan hydrobromide).<br />Each Eletrivaz 40 mg Film-coated tablet contains 40 mg of eletriptan<br />(as eletriptan hydrobromide).<br />The other ingredients are Microcrystalline Cellulose (PH-112), Lactose<br />Monohydrate, Croscarmellose Sodium and Magnesium Stearate,<br />Hypromellose 2910 (6cps) (E464), Triacetin (E1518), Titanium Dioxide<br />(E171), Lactose monohydrate and FD&amp;C Yellow Aluminium Lake (E110).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Eletriptan Hydrobromide Tablets 40 mg: Orange colored, round, biconvex,
film coated tablets debossed with ‘E’ and ‘L’ separated by a break line on
one side and ‘40’ on the other side.
The score line is only to facilitate breaking for ease of swallowing and not
to divide into equal doses
Eletriptan Hydrobromide are supplied in 6’s pack (6’s Blister x 1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Manufacturer:<br />APL Healthcare Limited,<br />Unit-IV, Plot No.16, APIIC, Multi Products SEZ,<br />Menakuru Village, Naidupeta Mandal,<br />S.P.S.R. Nellore District, Andhra Pradesh, INDIA.<br />Marketing Authorization Holder:<br />Aurobindo Pharma Saudi Arabia Limited,<br />Jeddah, Saudi Arabia.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 09/2022, version number is 01.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي إليتريفاز على المادة الفعالة إليتريبتان. وإليتريفاز عضو بمجموعة من الأدوية تُسمى مضادات مستقبل<br />السيروتونين. السيروتونين هو مادة طبيعية توجد في الدماغ، وتساعد على تضييق الأوعية الدموية.<br />يُمكن استخدام إليتريفاز لعلاج الصداع النصفي الذي تصاحبه أو لا تصاحبه هالة لدي البالغين. قبل بدء الصداع<br />النصفي، قد تعاني من طور يُسمى الهالة، ويتضمن اضطرابات بصرية وتنميل واضطرابات بالكلام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تأخذ إليتريفاز<br />&bull; إذا كنت تعاني من حساسية ) مفرط التحسس (لإليتريبتان أو أي من المكونات الأخرى لهذا الدواء ) المذكورة<br />.) في القسم 6<br />&bull; إن كنت مصابًا بأمراض خطيرة بالكبد أو الكلى.<br />&bull; إن كنت مصابًا بارتفاع متوسط إلى شديد بضغط الدم، أو ضغط دم بسيط غير مُعالج.<br />&bull; إن أُصبت قب ًالبمشاكل قلبية ) مثل الأزمة القلبية أو الذبحة الصدرية أو فشل القلب أو نظم القلب غير<br />الطبيعي بشكل كبير ) اضطراب النظم (أو الضيق المؤقت والمفاجئ بأحد الشرايين التاجية(.<br />&bull; إن كانت دورتك الدموية ضعيفة ) مرض وعائي طرفي(.<br />&bull; إن أُصبت من قبل بالسكتة الدماغية ) حتى الضعيفة منها التي تمتد لدقائق أو ساعات محدودة(.<br />&bull; إن كنت قد أخذت إيرجوتامين أو أدوية مماثلة لإيرجوتامين ) بما في ذلك ميثايسيرجيد (خلال 24 ساعة<br />قبل أخذ إليتريفاز أو بعده. إن كنت تأخذ أي أدوية أخرى تنتهي ب &ldquo;تريبتان&rdquo; ) مثل سوماتريبتان<br />وريزاتريبتان وناراتريبتان وزولميتريبتان وألموتريبتان وفروفاتريبتان(.<br />من فضلك استشر طبيبك ولا تأخذ إليتريفاز إن انطبق ما ذُكر عليك أو كان ينطبق عليك في أي وقت مضى.</p><p>التحذيرات والاحتياطات<br />&bull; إن كنت مصابًا بالسكري.<br />&bull; إن كنت مدخنًا أو تتبع علاج استبدال النيكوتين.<br />&bull; إن كنت ذكرًا أكبر من 40 عامًا.<br />&bull; إن كنتِ أنثى في سن الإياس.<br />&bull; إن كنت مصابًا أو أي من أفراد عائلتك بمرض الشريان التاجي.<br />&bull; إن كنت قد أُعلمت من قبل باحتمالية زيادة تعرضك للأمراض القلبية، ناقش ذلك مع طبيبك قبل أخذ<br />إليتريفاز.<br />الاستخدام المتكرر لأدوية الصداع النصفي<br />في حالة تكرار استخدام إليتريفاز أو أي أدوية أخرى لعلاج الصداع النصفي على مدار أيام أو أسابيع عديدة،<br />قد يتسبب ذلك في صداع طويل المدى. أعلم الطبيب في حالة معاناتك من ذلك، فقد تحتاج لوقف العلاج لفترة.<br />الأدوية الأخرى وإليتريفاز<br />أعلم طبيبك إن كنت تأخذ أو أخذت حديثًا أو قد تأخذ أي أدوية أخرى.</p><p dir="RTL"><strong>قد يتسبب أخذ إليتريفاز مع بعض الأدوية في آثار جانبية خطيرة. لا تستعمل إليتريفاز</strong><strong>:</strong></p><p dir="RTL">&bull; إن كنت قد أخذت إيرجوتامين أو أدوية مماثلة لإيرجوتامين ) بما في ذلك ميثايسيرجيد (خلال 24 ساعة</p><p dir="RTL">قبل أخذ إليتريفاز أو بعده.</p><p dir="RTL">&bull; إن كنت تأخذ أي أدوية أخرى تنتهي ب &ldquo;تريبتان&rdquo; ) مثل سوماتريبتان وريزاتريبتان وناراتريبتان</p><p dir="RTL">وزولميتريبتان وألموتريبتان وفروفاتريبتان(.</p><p dir="RTL">قد تؤثر بعض الأدوية على آلية عمل إليتريفاز، أو قد يُخفض إليتريفاز نفسه من تأثير بعض الأدوية</p><p dir="RTL">الأخرى عند أخذهما في نفس الوقت. ويتضمن ذلك:</p><p dir="RTL">&bull; الأدوية المستخدمة لعلاج العدوات الفطرية ) مثل كيتوكونازول وإيتراكونازول(.</p><p dir="RTL">&bull; الأدوية المستخدمة لعلاج العدوات البكتيرية ) مثل إريثرومايسين وكلاريثرومايسين وجوسامايسين(.</p><p dir="RTL">&bull; الأدوية المستخدمة لعلاج متلازمة نقص المناعة المكتسبة ( AIDS) وفيروس نقص المناعة البشرية (HIV)</p><p dir="RTL">مثل ريتونافير وإندينافير ونيلفينافير.</p><p dir="RTL">يجب عدم أخذ مستحضر عُشبة القديس جون العُشبي &nbsp;( <em>Hypericum perforatum</em>) مع هذا الدواء في نفس</p><p dir="RTL">الوقت. إن كنت قد أخذت عُشبة القديس جون بالفعل، استشر طبيبك قبل التوقف عن أخذ مستحضر عُشبة</p><p dir="RTL">القديس جون.</p><p dir="RTL">أعلم الطبيب قبل بدء العلاج بإليتريبتان إن كنت تأخذ بعض الأدوية ) عادة ما تُسمى مثبطات إعادة أخذ</p><p dir="RTL">السيروتونين الانتقائية) &nbsp;( SSRIأو مثبطات أعادة أخذ السيروتونين-نوريبينيفرين &nbsp;(SNRIs) لعلاج الاكتئاب والاضطرابات العقلية الأخرى. قد تتسبب تلك الأدوية في زيادة خطر الإصابة بمتلازمة السيروتونين</p><p dir="RTL">أثناء أخذها مع بعض أدوية الصداع النصفي. انظر القسم 4 &ldquo;الآثار الجانبية المحتملة&rdquo; للمزيد من المعلومات</p><p dir="RTL">حول متلازمة السيروتونين.</p><p dir="RTL">إليتريفاز مع الطعام والشراب<br />يمكنك أخذ إليتريفاز قبل الطعام والشراب أو بعدهم.<br />الحمل والرضاعة الطبيعية<br />اطلبِ من طبيبك أو الصيدلي النصيحة قبل أخذ أي دواء.<br />إذا كنتِ حام ًالأو ترضعين رضاعة طبيعية، أو تعتقدين أنك ربما تكونين حاملاً أو تخططين للحمل، فاطلبي<br />نصيحة طبيبك قبل تناول هذا الدواء.<br />يُفضل تجنب الإرضاع الطبيعي لمدة 24 ساعة بعد أخذ هذا الدواء.<br />القيادة واستخدام الآلات<br />قد يتسبب إليتريفاز أو الصداع النصفي نفسه في شعورك بالنعاس، وكذلك قد يتسبب هذا الدواء في شعورك<br />بالدوخة. لذا تجنب القيادة واستعمال الآلات أثناء أزمة الصداع النصفي أو بعد أخذ دواءك.</p><p dir="RTL"><strong>يحتوي إليتريفاز على اللاكتوز وصبغة أصفر غروب الشمس الألومنيوم الترسيبية </strong><strong>)</strong><strong> 110</strong><strong>( E</strong><strong>والصوديوم</strong></p><p dir="RTL">اللاكتوز هو أحد أنواع السكريات. إذا أخبرك طبيبك بعدم قدرتك على تحمل بعض السكريات، فعليك الاتصال</p><p dir="RTL">بطبيبك قبل أخذ هذا الدواء.</p><p dir="RTL">قد تتسبب صبغه FD&amp;C &nbsp;أصفر الألومنيوم الترسيبية &nbsp;) E110رقم 6) في حدوث تفاعلات تحسسيه</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>خذ هذا الدواء دائمًا كما أخبرك طبيبك، وتحقق من طبيبك أو الصيدلي إن لم تكن متأكدًا.<br />البالغون<br />يُمكن أخذ الدواء في أي وقت بعد بدء الصداع النصفي، ولكن يُفضل أخذه في أقرب وقت ممكن. وفي جميع<br />الأحوال، يجب أن تأخذ إليتريفاز فقط أثناء طور الصداع النصفي. يجب ألا تأخذ هذا الدواء لمنع أزمة الصداع<br />النصفي.<br />&bull; جرعة البدء المعتادة هي قرص واحد 40 مجم.<br />&bull; ابتلع كل قرص كام ًالمع بعض الماء.<br />&bull; إن لم يُخفف القرص الأول من الصداع النصفي، لا تأخذ قرصًا آخر لعلاج نفس النوبة.<br />&bull; إن اختفى الصداع النصفي بعد القرص الأول ثم عاد مرة ثانية، يمكنك أخذ قرص ثانِ. ومع ذلك، يجب أن<br />تنتظر ساعتين على الأقل بعد أخذ القرص الأول كي تستطيع أخذ القرص الثاني.<br />&bull; يجب ألا تأخذ أكثر من 80 مجم ) قرصان 40 مجم (خلال 24 ساعة.<br />&bull; أعلم طبيبك إن وجدت أن جرعة قرص واحد 40 مجم لا تُخفف الصداع النصفي، فقد يقرر زيادة الجرعة<br />لقرصين 40 مجم للنوبات المستقبلية.<br />الاستخدام مع الأطفال والمراهقين الأقل من 18 عام<br />لا يوصى باستعمال أقراص إليتريفاز مع الأطفال أو المراهقين الذين تقل أعمارهم عن 18 عامًا.<br />كبار السن<br />لا يوصى باستعمال أقراص إليتريفاز للمرضى الأكبر من 65 عام.<br />القصور الكلوي<br />يُمكن استخدام هذا الدواء مع المرضى المصابين بمشاكل كلوية بسيطة أو متوسطة، وتكون جرعة البدء<br />الموصي بها مع هؤلاء المرضى هي 20 مجم، كما يجب ألا تتعدى الجرعة الإجمالية اليومية 40 مجم.<br />سيُعلمك الطبيب بمقدار الجرعة الواجب أخذها.<br />القصور الكبدي<br />يُمكن استخدام هذا الدواء مع المرضى المصابين بمشاكل كبدية بسيطة أو متوسطة، ولا حاجة لتعديل الجرعة<br />لدي مرضى القصور الكبدي البسيط أو المتوسط.<br />إذا أخذت أكثر مما يجب من إليتريفاز<br />إذا أخذت أكثر مما يجب من إليتريفاز دون قصد، تواصل مع طبيبك على الفور، أو اذهب إلى قسم الطوارئ<br />بأقرب مستشفى. خذ دائمًا عبوة الدواء الموسمة معك، سواء كان بها دواء متبقي أو لا. تتضمن الآثار الجانبية<br />الناجمة عن أخذ الكثير من إليتريفاز ارتفاع ضغط الدم ومشاكل بالقلب.</p><p>إذا نسيت تناول إليتريفاز<br />إذا نسيت أخذ جرعة، خذها بمجرد تذكرك، مالم يكن وقت الجرعة التالية قد حان. لا تأخذ جرعة مزدوجة<br />للتعويض عن الجرعة المنسية.<br />تحدث مع طبيبك أو الصيدلي إن كانت لديك أي أسئلة إضافية حول استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يتسبب هذا الدواء بآثار جانبية، بالرغم من عدم إصابة الجميع بها.<br />أعلم طبيبك على الفور إذا عانيت من أي من الأعراض التالية بعد أخذ هذا الدواء.<br />&bull; أزيز مفاجئ أو صعوبة في التنفس أو تورم بجفني العينين أو الوجه أو الشفتين أو طفح أو حكة ) تُصيب<br />بوجه خاص الجسم بأكمله(، فقد تكون تلك أعراض لتفاعل فرط حساسية.<br />&bull; ألم وضيق بالصدر قد يكون شديدًا وقد يشمل الحلق. قد تكون تلك أعراض لمشاكل بالدورة الدموية للدم<br />)مرض القلب الإقفاري(.<br />&bull; علامات وأعراض متلازمة السيروتونين التي قد تتضمن الأرق والهلاوس وفقدان تحديد الاتجاه ونبض<br />القلب السريع وارتفاع درجة حرارة الجسم والتغيرات السريعة بضغط الدم وردود الفعل المفرطة.<br />&bull; تيبس ) زيادة التوتر العضلي(، ضعف عضلي، ألم بالظهر، ألم بالعضلات<br />&bull; شعور عام بالضعف، شعور بالحرارة، ارتعاش، سيلان الأنف، تعرق، وخز أو شعور غير معتاد، دفق،<br />ألم<br />الآثار الجانبية الأخرى التي قد تحدث:<br />شائعة<br />)قد تؤثر على 1 لكل 10 شخص (<br />&bull; ألم أو ضيق أو ضغط بالصدر، خفقان بالقلب، ارتفاع معدل نبض القلب<br />&bull; دوخة، شعور بالترنح أو الدوخة ) دوار(، صداع، شعور بالنعاس، انخفاض الشعور باللمس أو الألم<br />&bull; التهاب الحلق، ضيق الحلق، جفاف الفم<br />&bull; ألم بالبطن والمعدة، عسر هضم ) اضطراب المعدة(، غثيان ) شعور باضطراب وعدم راحة بالمعدة أو<br />البطن تصاحبه رغبة في التقيؤ (<br />&bull; تيبس ) زيادة التوتر العضلي(، ضعف عضلي، ألم بالظهر، ألم بالعضلات<br />&bull; شعور عام بالضعف، شعور بالحرارة، ارتعاش، سيلان الأنف، تعرق، وخز أو شعور غير معتاد، دفق، ألم</p><p>غير شائعة<br />)قد تؤثر على 1 لكل 100 شخص (<br />&bull; صعوبة بالتنفس، تثاؤب<br />&bull; تورم بالوجه أو اليدين والقدمين، التهاب أو عدوى باللسان، طفح جلدي، حكة<br />&bull; زيادة الشعور باللمس أو الألم ) زيادة الإحساس(، فقدان التوازن، بطء الحركة أو انخفاضها، رعشة،<br />اضطراب الكلام<br />&bull; عدم الشعور بالذات ) تبدد الشخصية(، اكتئاب، تفكير غريب، شعور بالتهيج، شعور بالارتباك، تقلبات<br />المزاج ) ابتهاج(، فترات من عدم الاستجابة ) ذهول(، شعور عام بعدم الراحة، مرض أو فقدان الصحة<br />)وهن(، عدم النوم ) أرق (<br />&bull; فقدان الشهية وفقدان الوزن، اضطرابات التذوق، ظمأ<br />&bull; تحلل المفاصل ) فُصال(، ألم بالعظام، ألم بالمفاصل<br />&bull; زيادة الحاجة لإخراج الماء ) التبول(، مشاكل بالتبول، إخراج كميات كبيرة من البول، إسهال<br />&bull; رؤية غير معتادة، ألم بالعينين، عدم تحمل الضوء، جفاف العينين أو الدموع<br />&bull; ألم بالأذن، رنين في الأذنين ) طنين (<br />&bull; ضعف الدورة الدموية ) اضطراب وعائي طرفي (<br />نادرة<br />)قد تؤثر على 1 لكل 1,000 شخص (<br />&bull; صدمة، ربو، شرى ) أرتيكاريا(، اضطرابات بالجلد، تورم اللسان<br />&bull; عدوى الحلق أو الصدر، تورم العقد الليمفاوية<br />&bull; بطء نبض القلب<br />&bull; هشاشة عاطفية ) تقلبات المزاج (<br />&bull; تحلل المفاصل ) فُصال(، اضطرابات عضلية، وخز<br />&bull; إمساك، التهاب المريء، تجشؤ<br />&bull; ألم بالثدي، دورات شهرية كثيفة أو ممتدة<br />&bull; عدوى بالعينين ) التهاب الملتحمة (<br />&bull; تغير الصوت<br />الآثار الجانبية الأخرى المُبلغ عنها تتضمن الإغماء وارتفاع ضغط الدم والتهاب الأمعاء الغليظة والقيء<br />والحالات المرتبطة بالدماغ والأوعية الدموية واضطراب تدفق الدم للقلب والأزمة القلبية والتشنجات المرتبطة<br />بعضلة/شرايين القلب.<br />قد يأخذ الطبيب أيضًا عينات دم دورية للتحقق من ارتفاع مستويات الإنزيمات الكبدية أو أي مشاكل بالدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ابق هذا الدواء بعيدا عن نظر الأطفال ومتناول أيديهم.<br />لا تستخدم هذا الدواء بعد تاريخ الانتهاء المذكور على الشريط أو العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر<br />يوم في ذلك الشهر.<br />يُحفظ في درجة حرارة أقل من 30 مئوية.<br />لا تتخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية، واسأل الصيدلي عن كيفية التخلص<br />من الأدوية التي لم تعد بحاجة إليها. هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي إليتريبتان( في صورة إليتريبتان هيدروبروميد).</p><p dir="RTL">يحتوي كل قرص مغلف من إليتريفاز 40 مجم على 40 مجم إليتريبتان ) في صورة إليتريبتان هيدروبروميد(.</p><p dir="RTL">المكونات الأخرى هي سيليولوز دقيق التبلور PH112 ، لاكتوز أحادي الماء، كروسكارميلوز صوديوم</p><p dir="RTL">ستيرات ماغنسيوم، هيبروميلوز 2910 &nbsp;6cps ( E464) ترياسيتين &nbsp;1518E ثاني أكسيد التيتانيوم ) E171</p><p dir="RTL">لاكتوز أحادي الماء ، أصفر الألومنيوم الترسيبية ) E110 ، صبغه FD&amp;C&nbsp;&nbsp;E171</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إليتريبتان هيدروبروميد أقراص 40 مجم: أقراص مستديرة مغلفة برتقالية اللون ثنائية التحدب، محفور على</p><p dir="RTL">أحد جانبيها &rdquo;E&ldquo; و &rdquo;L&ldquo; و على الجانب الآخر &ldquo; 40 &rdquo; يفصلهما خط قطعي</p><p dir="RTL">خط الشطر هو فقط لتسهيل الكسر لسهولة البلع وليس للتقسيم إلى جرعات متساوية</p><p dir="RTL">يُورد إليتريفاز في عبوة تحتوي على 6 أقراص ( شريط واحد يحتوي على 6 أقراص(.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>المُصنع:<br />إيه بي إل هيلثكير المحدودة، الهند.<br />حامل ترخيص التسويق:<br />أوروبيندو فارما السعودية المحدودة،<br />جدة، المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اعتمدت هذه النشرة في 09/2022 رقم الإصدار هو 0
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eletrivaz (Eletriptan Hydrobromide Tablets 40 mg)
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                COMPOSITIONS: Each film-coated tablet contains:
Eletriptan Hydrobromide equivalent to Eletriptan Hydrobromide 40 mg


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Eletriptan Hydrobromide Tablets 40 mg:
Orange colored, round, biconvex, film coated tablets debossed with ‘E’ and ‘L’ separated by a break line on one side and ‘40’ on the other side.
the score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses
For a full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Eletriptan Hydrobromide is indicated in adults for the acute treatment of the headache phase of migraine attacks, with or without aura.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Posolog</u>y</p><p dir="ltr">&nbsp;</p><p dir="ltr">Eletriptan tablets should be taken as early as possible after the onset of migraine headache but they are also effective if taken at a later stage during a migraine attack.</p><p dir="ltr">Eletriptan, if taken during the aura phase, has not been demonstrated to prevent migraine headache and therefore Eletriptan should only be taken during the headache phase of migraine.</p><p dir="ltr">Eletriptan tablets should not be used prophylactically<em>.</em></p><p dir="ltr"><!--[if gte vml 1]><o:wrapblock><v:shape id="_x0000_s1026"
  style='position:absolute;margin-left:180.1pt;margin-top:8.05pt;width:3.5pt;
  height:.05pt;z-index:251658240;mso-wrap-distance-left:0;
  mso-wrap-distance-right:0;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:text' coordsize="70,1" o:allowincell="f"
  path="m,hhl69,e" filled="f" strokeweight=".28114mm">
  <v:path arrowok="t"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" dir="ltr"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="6" height="2" src="file:///C:/Users/USER/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" /></td></tr></tbody></table><p dir="ltr"><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p dir="ltr"><em><u>Adults (18-65 years of age):</u></em></p><p dir="ltr">The recommended initial dose is 40 mg.</p><p dir="ltr"><em>If headache returns within 24 hours</em>: If the migraine headache recurs within 24 hours of an initial response, a second dose of the same strength of Eletriptan has been shown to be effective in treating the recurrence. If a second dose is required, it should not be taken within 2 hours of the initial dose.</p><p dir="ltr"><em>If no response is obtained: </em>If a patient does not achieve a headache response to the first dose of Eletriptan within 2 hours, a second dose should not be taken for the same attack as clinical trials</p><p dir="ltr">have not adequately established efficacy with the second dose. Clinical trials show that patients who do not respond to the treatment of an attack are still likely to respond to the treatment of a subsequent attack.</p><p dir="ltr">Patients who do not obtain satisfactory efficacy after an appropriate trial of 40 mg, (e.g., good tolerability and failure to respond in 2 out of 3 attacks), may be effectively treated with 80 mg (2 x 40 mg) in subsequent migraine attacks (see section Pharmacodynamic properties). A second dose of 80 mg should not be taken within 24 hours.</p><p dir="ltr">The maximum daily dose should not exceed 80 mg.</p><p dir="ltr"><em><u>Elderly patients</u></em></p><p dir="ltr">The safety and effectiveness of eletriptan in patients over 65 years of age have not been systematically evaluated due to the small number of such patients in clinical trials. Use of eletriptan in the elderly is therefore not recommended.</p><p dir="ltr"><em><u>&nbsp;Paediatric population </u>&nbsp;Adolescents (12-17 years of age)</em></p><p dir="ltr">The efficacy of eletriptan in adolescents aged 12 to 17 years has not been established. Current available data are described in section Pharmacokinetic properties but no recommendation on a posology can be made.</p><p dir="ltr"><em>Children (6-11 years of age)</em></p><p dir="ltr">The safety and efficacy of eletriptan in children aged 6 to 11 years has not been established. Current available data are described in section Pharmacokinetic properties but no recommendation on a posology can be made.</p><p dir="ltr"><em><u>Patients with hepatic impairment</u></em></p><p dir="ltr">No dose adjustment is required in patients with mild or moderate hepatic impairment. As Eletriptan has not been studied in patients with severe hepatic impairment, it is contraindicated in these patients.</p><p dir="ltr"><em><u>Patients with renal imp</u>airment</em></p><p dir="ltr">As the blood pressure effects of Eletriptan are amplified in renal impairment (see section Special warnings and precautions for use), a 20 mg initial dose, is recommended in patients with mild or moderate renal impairment. The maximum daily dose should not exceed 40 mg. Eletriptan is contra- indicated, in patients with severe renal impairment<strong>.</strong></p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Method of administration</u></p><p dir="ltr">The tablets should be swallowed whole with water.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eletriptan is contraindicated in patients with
•	hypersensitivity to Eletriptan hydrobromide or to any of the excipients listed in section List of excipients.
•	severe hepatic or severe renal impairment.
•	moderately severe or severe hypertension, or untreated mild hypertension.
•	confirmed coronary heart disease, including ischaemic heart disease (angina pectoris, previous myocardial infarction or confirmed silent ischaemia). Patients with coronary artery vasospasm (Prinzmetal's angina), objective or subjective symptoms of ischaemic heart disease.
•	significant arrhythmias or heart failure.
•	peripheral vascular disease.
•	A history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA).
•	Administration of ergotamine, or derivatives of ergotamine (including methysergide), within 24hr before or after treatment with Eletriptan (see section Interaction with other medicinal products and other forms of interaction).
•	concomitant administration of other 5-HT1 receptor agonists with Eletriptan.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Eletriptan should not be used together with potent CYP3A4 inhibitors e.g., ketoconazole, itraconazole, erythromycin, clarithromycin, josamycin and protease inhibitors (ritonavir, indinavir and nelfinavir).</p><p dir="ltr">Eletriptan should only be used where a clear diagnosis of migraine has been established. Eletriptan is not indicated for the management of hemiplegic, ophthalmoplegic<strong>, </strong>or basilar migraine.</p><p dir="ltr">Eletriptan should not be given for the treatment of &#39;atypical&#39; headaches, i.e. headaches, which may be related to a possibly serious condition (stroke, aneurysm rupture) where cerebrovascular vasoconstriction may be harmful.</p><p dir="ltr">Eletriptan can be associated with transient symptoms including chest pain and tightness, which may be intense and involve the throat (see section Undesirable effects). Where such symptoms are thought to indicate ischaemic heart disease, no further dose should be taken and appropriate evaluation should be carried out.</p><p dir="ltr"><u>Patients with cardiac failure</u></p><p dir="ltr">Eletriptan should not be given without prior evaluation, to patients in whom unrecognised cardiac disease is likely, or to patients at risk of coronary artery disease (CAD) [e.g., patients with hypertension, diabetes, smokers or users of nicotine substitution therapy, men over 40 years of age, post- menopausal women and those with a strong family history of CAD]. Cardiac evaluations may not identify every patient who has cardiac disease and, in very rare cases, serious cardiac events may occur, in patients without underlying cardiovascular disease when 5- HT1 agonists have been administered. Patients in whom CAD is established, should not be given Eletriptan (see section Contraindications). 5- HT1 receptor agonists have been associated</p><p dir="ltr">&nbsp;</p><p dir="ltr">with coronary vasospasm. In rare cases, myocardial ischaemia or infarction, may be seen with 5- HT1 receptor agonists.</p><p dir="ltr">Undesirable effects may be more common during concomitant use of triptans and herbal preparations containing St. John&#39;s wort (Hypericum perforatum).</p><p dir="ltr">Within the clinical dose range, slight and transient increases in blood pressure have been seen with eletriptan doses of 60 mg or greater. However, these increases have not been associated with clinical sequelae in the clinical trial programme. The effect was much more pronounced in renally impaired and elderly subjects. In renally impaired subjects, the range of mean maximum increases in systolic blood pressure was 14 -17mmHg (normal 3mmHg) and for diastolic blood pressure was 14 -21mmHg (normal 4mmHg). In elderly subjects, the mean maximum increase in systolic blood pressure was 23mmHg compared with 13mmHg in young adults (placebo 8mmHg). Post-marketing reports of increases in blood pressure have also been received for patients taking 20 and 40 mg doses of eletriptan, and in non-renally impaired and non-elderly patients.</p><p dir="ltr"><u>Medication overuse headache (MOH)</u></p><p dir="ltr">Prolonged use of any painkiller for headaches can make them worse. If this situation is experienced or suspected, medical advice should be obtained and treatment should be discontinued. The diagnosis of MOH should be suspected in patients who have frequent or daily headaches despite (or because of) the regular use of headache medications.</p><p dir="ltr"><u>Serotonin syndrome</u></p><p dir="ltr">Serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) may be observed following concomitant treatment with triptans and selective serotonin reuptake inhibitors (SSRIs) or serotonin noradrenaline reuptake nhibitors (SNRIs). These reactions can be severe. If concomitant treatment with Eletriptan and an SSRI or SNRI is clinically warranted, appropriate observation of the patient is advised, particularly during treatment initiation, with dose increases, or with addition of another serotonergic medication.</p><p dir="ltr">This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p dir="ltr">This medicinal product also contains sunset yellow which may cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Effect of other medicinal products on Eletriptan</u></p><p dir="ltr">In the pivotal clinical trials of eletriptan no evidence of interaction with beta-blockers, tricyclic antidepressants, selective serotonin reuptake inhibitors and flunarizine was reported but data from formal clinical interaction studies with these medicinal products are not available.</p><p dir="ltr">&nbsp;</p><p dir="ltr">Population pharmacokinetic analysis of clinical studies has suggested that the following medicinal products (beta-blockers, tricyclic antidepressants, selective serotonin re-uptake inhibitors, oestrogen based hormone replacement therapy, oestrogen containing oral contraceptives and calcium channel blockers) are unlikely to have an effect on the pharmacokinetic properties of eletriptan.</p><p dir="ltr">Eletriptan is not a substrate for MAO. Therefore there is no expectation of an interaction between Eletriptan and MAO inhibitors. Therefore no formal interaction study has been undertaken.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Effect of Eletriptan on other medicinal products</u></p><p dir="ltr">There is no <em>in vitro </em>or <em>in vivo </em>evidence that clinical doses (and associated concentrations) of Eletriptan will inhibit or induce cytochrome P450 enzymes including CYP3A4 drug metabolising enzymes and therefore it is considered that Eletriptan is unlikely to cause clinically important drug interactions mediated by these enzymes.</p><p dir="ltr"><em>Selective Serotonin Reuptake Inhibitors (SSRIs) /Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) and Serotonin Syndrome:</em></p><p dir="ltr">There have been reports describing patients with symptoms compatible with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the use of selective serotonin reuptake inhibitors (SSRIs) or serotonin noradrenaline reuptake inhibitors (SNRIs) and triptans.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pregnancy: For Eletriptan no clinical data on exposed pregnancies are available.</p><p dir="ltr">Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development. Eletriptan should be used during pregnancy only if clearly needed.</p><p dir="ltr">Breast-feeding: Eletriptan is excreted in human breast milk. In one study of 8 women given a single dose of 80 mg, the mean total amount of eletriptan in breast milk over 24 hours in this group was 0.02% of the dose. Nevertheless, caution should be exercised when considering the administration of Eletriptan to women who are breast-feeding. Infant exposure can be minimised by avoiding breast-feeding for 24 hours after treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Eletriptan has moderate influence on the ability to drive and use machines. Migraine or treatment with Eletriptan may cause drowsiness or dizziness in some patients. Patients should be advised to evaluate their ability to perform complex tasks such as driving during migraine attacks and following administration of Eletriptan.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Eletriptan has been administered in clinical trials to over 5000 subjects, taking one or two doses of Eletriptan 20 or 40 or 80 mg. The most common adverse reactions noted were asthenia, somnolence, nausea and dizziness. In randomized clinical studies using doses of 20, 40 and 80 mg, a trend for a dose- dependency of the incidence of adverse events has been shown.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse reactions (with an incidence &ge;1% and higher than placebo) were reported in patients treated with therapeutic doses in clinical trials. Events are categorized by frequency as common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), or rare (&ge;1/10,000 to</p><p>&lt;1/1,000).</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td></tr><tr><td style="vertical-align:top"><p>pharyngitis, and rhinitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>respiratory tract infection</p></td><td style="vertical-align:top"><p>Infections and infestations:</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>lymphadenopathy</p></td><td style="vertical-align:top"><p>Blood and the lymphatic</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>anorexia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Metabolism and nutrition</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>thinking abnormal, agitation, confusion, depersonalisation, euphoria, depression, and</p><p>insomnia</p></td><td style="vertical-align:top"><p>emotional lability</p></td><td style="vertical-align:top"><p>Psychiatric disorders:</p></td></tr><tr><td style="vertical-align:top"><p>somnolence, headache, dizziness, tingling or abnormal sensation, hypertonia, hypoaesthesia, and myasthenia</p></td><td style="vertical-align:top"><p>tremor, hyperaesthesia, ataxia, hypokinesia, speech disorder, stupor, and taste perversion</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Nervous system disorders:</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>abnormal vision, eye</p><p>pain, photophobia, and lacrimation disorder</p></td><td style="vertical-align:top"><p>conjunctivitis</p></td><td style="vertical-align:top"><p>Eye disorders:</p></td></tr><tr><td style="vertical-align:top"><p>vertigo</p></td><td style="vertical-align:top"><p>ear pain, tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td></tr><tr><td style="vertical-align:top"><p>palpitation,</p><p>and tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>bradycardia</p></td><td style="vertical-align:top"><p>Cardiac disorders:</p></td></tr><tr><td style="vertical-align:top"><p>flushing</p></td><td style="vertical-align:top"><p>peripheral vascular disorder</p></td><td style="vertical-align:top"><p>shock</p></td><td style="vertical-align:top"><p>Vascular disorders:</p></td></tr><tr><td style="vertical-align:top"><p>throat tightness</p></td><td style="vertical-align:top"><p>dyspnea, respiratory disorder and yawning</p></td><td style="vertical-align:top"><p>asthma and voice alteration</p></td><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal</p></td></tr><tr><td style="vertical-align:top"><p>abdominal pain, nausea, dry mouth,</p><p>and dyspepsia</p></td><td style="vertical-align:top"><p>diarrhoea, and glossitis</p></td><td style="vertical-align:top"><p>constipation, oesophagitis, tongue oedema</p><p>and eructation</p></td><td style="vertical-align:top"><p>Gastrointestinal disorders:</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>hyperbilirubinaemi a, and increased</p></td><td style="vertical-align:top"><p>Hepato-biliary disorders:</p></td></tr><tr><td style="vertical-align:top"><p>sweating</p></td><td style="vertical-align:top"><p>rash and pruritis</p></td><td style="vertical-align:top"><p>skin disorder and urticaria</p></td><td style="vertical-align:top"><p>Skin and subcutaneous tissue</p></td></tr></tbody></table><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>back pain, myalgia</p></td><td style="vertical-align:top"><p>arthralgia, arthrosis and bone pain</p></td><td style="vertical-align:top"><p>arthritis, myopathy and twitching</p></td><td style="vertical-align:top"><p>Musculoskeletal, connective tissue and bone disorders:</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>increased urinary frequency, urinary tract disorder and polyuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Renal and urinary disorders:</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>breast pain and menorrhagia</p></td><td style="vertical-align:top"><p>Reproductive system and breast disorders:</p></td></tr><tr><td style="vertical-align:top"><p>feeling hot, asthenia, chest symptoms (pain, tightness, pressure), chills</p><p>and pain</p></td><td style="vertical-align:top"><p>malaise, face oedema, thirst, oedema and peripheral oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>General disorders and administration site conditions:</p><p>&nbsp;</p><p dir="ltr">The common adverse events seen with Eletriptan are typical of adverse events reported with 5-HT1 agonists as a class. In post-marketing experience, the following undesirable effects have been reported:</p><p dir="ltr">Immune system disorders: allergic reactions, some of which may be serious, including angioedema Nervous system disorders: serotonin syndrome, rare cases of syncope, cerebrovascular accident Vascular disorders: hypertension</p><p dir="ltr">Cardiac disorders: myocardial ischaemia or infarction, arteriospasm coronary</p><p dir="ltr">Gastrointestinal disorders: as with some other 5HT 1B/1D agonists, rare reports of ischaemic colitis have been received, vomiting.</p></td></tr></tbody></table><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Subjects have received single doses of 120 mg without significant adverse effects. However based on the pharmacology of this class, hypertension or other more serious cardiovascular symptoms could occur on overdose.</p><p dir="ltr">In cases of overdose, standard supportive measures should be adopted as required. The elimination half- life of Eletriptan is about 4 hours, and therefore monitoring of patients and provision of general supportive therapy after overdose with Eletriptan should continue for</p><p dir="ltr">&nbsp;</p><p dir="ltr">at least 20 hours or while signs and symptoms persist.</p><p dir="ltr">It is unknown what effect haemodialysis or peritoneal dialysis has on the serum concentrations of Eletriptan.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Pharmacotherapeutic group: Selective Serotonin (5HT1) receptor agonists ATC code: N02CC06 <u>Mechanism of action</u></p><p dir="ltr">Eletriptan is a selective agonist at the vascular 5-HT1B and neuronal 5-HT1D receptors. Eletriptan also exhibits high affinity for the 5-HT1F receptor which may contribute to its anti-migraine mechanism of action. Eletriptan has modest affinity for the human recombinant 5-HT1A, 5-HT2B, 5-HT1E and 5- HT7 receptors.</p><p dir="ltr"><u>Clinical efficacy and safety</u></p><p dir="ltr">The efficacy and safety of eletriptan in the acute treatment of migraine has been evaluated in 10 placebo- controlled trials involving more than 6000 patients (all treatment groups) at doses of 20 to 80 mg. Headache relief occurred as early as 30 minutes following oral dosing. Response rates (i.e., reduction of moderate or severe headache pain to no or mild pain) 2 hours after dosing were 59-77% for the 80 mg dose, 54-65% for the 40 mg dose, 47-54% for the 20 mg dose, and 19-40% following placebo. Eletriptan was also effective in the treatment of associated symptoms of migraine such as vomiting, nausea, photophobia and phonophobia.</p><p dir="ltr">The recommendation for dose titration to 80 mg, is derived from open label long term studies and from a short term double blind study, where only a trend towards statistical significance was observed.</p><p dir="ltr">Eletriptan remains effective in menstrually associated migraine. Eletriptan, if taken during the aura phase, has not been demonstrated to prevent migraine headache and therefore eletriptan should only be taken during the headache phase of migraine.</p><p dir="ltr">In a non placebo controlled pharmacokinetic study of patients with renal impairment, larger elevations</p><p dir="ltr">in blood pressure were recorded after an 80 mg dose of eletriptan than with normal volunteers (see section Special warnings and precautions for use). This cannot be explained by any pharmacokinetic changes and so may represent a specific pharmacodynamic response to eletriptan in patients with renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr"><u>Absorption</u></p><p dir="ltr">Eletriptan is rapidly and well absorbed across the gastro-intestinal tract (at least 81%) after oral administration. Absolute oral bioavailability across males and females is approximately 50%. The median Tmax is 1.5 hours after oral dosing. Linear pharmacokinetics were demonstrated over the clinical dose range (20-80 mg).</p><p dir="ltr">The AUC and Cmax of Eletriptan were increased by approximately 20-30% following oral administration with a high fat meal. Following oral administration during a migraine attack, there was a reduction of approximately 30% in AUC and Tmax was increased to 2.8 hours</p><p dir="ltr">Following repeated doses (20 mg three times daily) for 5-7 days, the pharmacokinetics of Eletriptan remained linear and accumulation was predictable. On multiple dosing of larger doses (40 mg three times daily and 80 mg two times daily), the accumulation of Eletriptan</p><p dir="ltr">&nbsp;</p><p dir="ltr">over 7 days was greater than predicted (approximately 40%).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><u>Distribution</u></p><p dir="ltr">The volume of distribution of Eletriptan following IV administration is 138L indicating distribution into the tissues. Eletriptan is only moderately protein bound (approximately 85%).</p><p dir="ltr"><u>Biotransformation</u></p><p dir="ltr"><em>In vitro </em>studies indicate that Eletriptan is primarily metabolised by hepatic cytochrome P-</p><p dir="ltr">450 enzyme CYP3A4. This finding is substantiated by increased plasma concentrations of Eletriptan following co-administration with erythromycin and ketoconazole<strong><em>, </em></strong>known selective and potent CYP3A4 inhibitor<strong><em>s</em></strong>. <em>In vitro </em>studies also indicate a small involvement of CYP2D6 although clinical studies do not indicate any evidence of polymorphism with this enzyme.</p><p dir="ltr">There are two major circulating metabolites identified that significantly contribute to plasma radioactivity following administration of C14-labelled Eletriptan. The metabolite formed by N- oxidation, has demonstrated no activity in animal <em>in vitro </em>models. The metabolite formed by N- demethylation, has been demonstrated to have similar activity to Eletriptan in animal <em>in vitro </em>models. A third area of radioactivity in plasma has not been formally identified, but is most likely to be a mixture of hydroxylated metabolites which have also been observed excreted in urine and faeces.</p><p dir="ltr">The plasma concentrations of the N-demethylated active metabolite are only 10-20% of those of parent and so would not be expected to significantly contribute to the therapeutic action of Eletriptan.</p><p dir="ltr"><u>Elimination</u></p><p dir="ltr">Mean total plasma clearance of Eletriptan following IV administration is 36 L/h with a resultant plasma half-life of approximately 4 hours. The mean renal clearance following oral administration is approximately 3.9 L/h. Non-renal clearance accounts for approximately 90% of the total clearance indicating that Eletriptan is eliminated primarily by metabolism.</p><p dir="ltr"><u>Pharmacokinetics in Special Patient Groups</u></p><p dir="ltr"><em><u>Gender</u></em></p><p dir="ltr">A meta analysis across clinical pharmacology studies and a population pharmacokinetic analysis of clinical trial data indicate that gender does not have any clinically significant influence on plasma concentrations of eletriptan.</p><p dir="ltr"><em><u>Elderly (over 65 years of age)</u></em></p><p dir="ltr">Though not statistically significant, there is a small reduction (16%) in clearance associated with a statistically significant increased half-life (from approximately 4.4 hours to 5.7 hours) between elderly (65-93 years) and younger adult patients.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&nbsp;</p><p dir="ltr"><em><u>Adolescents (12-17 years of age)</u></em></p><p dir="ltr">The pharmacokinetics of Eletriptan (40 mg and 80 mg) in adolescent migraine patients dosed between attacks, were similar to those seen in healthy adults.</p><p dir="ltr"><em><u>Children (6-11 years of age)</u></em></p><p dir="ltr">The clearance of Eletriptan is unchanged in children relative to adolescents<em>. </em>However the volume of distribution is lower in children resulting in higher plasma levels than would be predicted following the same dose in adults.</p><p dir="ltr"><em><u>Patients with hepatic impairment</u></em></p><p dir="ltr">Patients with hepatic impairment (Child-Pugh A and B) demonstrated a statistically significant increase in both AUC (34%) and half-life. There was a small increase in Cmax (18%). This small change in exposure is not considered clinically relevant.</p><p dir="ltr"><em><u>Patients with renal impairment</u></em></p><p dir="ltr">Patients with mild (creatinine clearance 61-89 ml/min), moderate (creatinine clearance 31-60 ml/min) or severe (creatinine clearance &lt;30 ml/min) renal impairment did not have any statistically significant alterations in their Eletriptan pharmacokinetics or plasma protein binding. Blood pressure elevations were observed in this group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Preclinical data, revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity and toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">The other ingredients are Microcrystalline Cellulose (PH-112), Lactose Monohydrate, Croscarmellose Sodium and Magnesium Stearate, Hypromellose 2910 (6cps) (E464), Triacetin (E1518), Titanium Dioxide (E171), Lactose monohydrate and FD&amp;C Yellow Aluminium Lake (E110).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">Blister pack</p><p dir="ltr">Eletrivaz are supplied in 6&rsquo;s pack&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (6&rsquo;s Blister x 1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p dir="ltr">No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aurobindo Pharma Saudi Arabia Limited, Jeddah, Saudi Arabia.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                September 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>